Insight Molecular Diagnostics (IMDX) Long-Term Investments (2017 - 2021)

Insight Molecular Diagnostics has disclosed Long-Term Investments across 5 years of filings, most recently posting $2.0 million for Q1 2021.

• Long-Term Investments for Q1 2021 came in at $2.0 million, down 80.87% year-over-year; the trailing twelve-month figure through Mar 2021 was $2.0 million (down 80.87% YoY), and the FY2020 annual result was $13.4 million, up 506.83% from the prior year.
• Long-Term Investments came in at $2.0 million for Q1 2021 at Insight Molecular Diagnostics, down from $13.4 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $13.9 million in Q3 2020 to a low of $120000.0 in Q4 2017.
• The 5-year median for Long-Term Investments is $2.0 million (2020), against an average of $4.7 million.
• Across the five-year window, Long-Term Investments soared 5271.21% in 2020 and tumbled 80.87% in 2021, its largest moves.
• Insight Molecular Diagnostics' Long-Term Investments stood at $120000.0 in 2017, then soared by 118.33% to $262000.0 in 2018, then surged by 743.89% to $2.2 million in 2019, then soared by 506.83% to $13.4 million in 2020, then tumbled by 84.83% to $2.0 million in 2021.
• The last three Long-Term Investments figures came in at $2.0 million (Q1 2021), $13.4 million (Q4 2020), and $13.9 million (Q3 2020), per Business Quant data.